The business of science, especially in life sciences, carries high risks and high rewards, both in terms of succesful therapeutic advancements and of reduction in human suffering.

Success rate is maximised as motivated partners, sharing the same project and integrating their best tecnologies, develop a partnership investing towards a common objective.

We have made this principle the Leitmotiv of our partnering strategy: we are looking for companies and corporations willing to forge collaborative R & D agreements in CNS and proliferative disorders, with risk sharing/profit sharing approaches.

At the same time we are interested in getting in touch with potential partners interested in licensing out molecules or other know-how in our research field which may be necessary to reach our corporate goals.

Our four-phase partnering evaluation process is short and to the point:

Phase I Brief initial evaluation by relevant R&D and Business Development groups;

Phase II In-depth R&D and business evaluation;

Phase III Agreement negotiation and due diligence;

Phase IV Final negotiation and closing of the agreement.

If you believe there may be the basis to discuss a partnership with Siena Biotech, please contact us. We will be glad to exchange our viewpoints.